Guangdong VTR Bio-Tech Co Ltd
SZSE:300381

Watchlist Manager
Guangdong VTR Bio-Tech Co Ltd Logo
Guangdong VTR Bio-Tech Co Ltd
SZSE:300381
Watchlist
Price: 6.95 CNY -1.28% Market Closed
Market Cap: 3.4B CNY
Section:
 

Relative Value

The Relative Value of one Guangdong VTR Bio-Tech Co Ltd stock under the Base Case scenario is 4.75 CNY. Compared to the current market price of 6.95 CNY, Guangdong VTR Bio-Tech Co Ltd is Overvalued by 32%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
4.75 CNY
Overvaluation 32%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4
P/S
P/S
Price to Sales
4
vs History
36
vs Industry
64
Median 3Y
4.2
Median 5Y
3.5
Industry
8.1
More Details
513.6
P/E
P/E
Price to Earnings
513.6
vs History
9
vs Industry
1
Median 3Y
202.1
Median 5Y
114.1
Industry
23.7
More Details
107.6
P/OCF
P/OCF
Price to OCF
107.6
vs History
4
vs Industry
10
Median 3Y
17.6
Median 5Y
16
Industry
22.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
2
Median 3Y
-14.6
Median 5Y
-13.6
Industry
25.7
More Details
1.3
P/B
P/B
Price to Book Value
1.3
vs History
73
vs Industry
53
Median 3Y
1.3
Median 5Y
1.5
Industry
3.3
More Details
3.3
EV/S
EV/S
Enterprise Value to Sales
3.3
vs History
17
vs Industry
60
Median 3Y
3.2
Median 5Y
3
Industry
8.4
More Details
7.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.7
vs History
30
vs Industry
47
Median 3Y
7.5
Median 5Y
7.5
Industry
10.4
More Details
32 527.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
32 527.5
vs History
0
vs Industry
0
Median 3Y
203.7
Median 5Y
18.1
Industry
5.9
More Details
32 527.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
32 527.5
vs History
0
vs Industry
0
Median 3Y
203.7
Median 5Y
18.1
Industry
6.4
More Details
88.7
EV/OCF
EV/OCF
Enterprise Value to OCF
88.7
vs History
4
vs Industry
12
Median 3Y
13.5
Median 5Y
13.5
Industry
8.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
3
Median 3Y
-9.9
Median 5Y
-7.8
Industry
6.4
More Details
1.3
EV/IC
EV/IC
Enterprise Value to IC
1.3
vs History
61
vs Industry
52
Median 3Y
1.4
Median 5Y
1.4
Industry
5.8
More Details

Multiples Across Competitors

Competitors Multiples
Guangdong VTR Bio-Tech Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Guangdong VTR Bio-Tech Co Ltd
SZSE:300381
3.3B CNY 4 513.6 32 527.5 32 527.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 178 916.3 -162 447.3 -197 262.9 -195 011.9
US
Abbvie Inc
NYSE:ABBV
378.8B USD 6.4 161.3 15.7 22.3
US
Amgen Inc
NASDAQ:AMGN
177.8B USD 4.9 25.4 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD 5.3 19.1 12.9 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD 9.6 30.5 22.3 23.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 061.2 -526 -572.7 -557.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD 5.4 16.9 16 18.2
AU
CSL Ltd
ASX:CSL
85B AUD 3.7 18.9 12.8 15.9
NL
argenx SE
XBRU:ARGX
42.4B EUR 13.7 32.1 55.1 56.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD 14.8 1 086.8 146.4 177.6
P/E Multiple
Earnings Growth PEG
CN
Guangdong VTR Bio-Tech Co Ltd
SZSE:300381
Average P/E: 211.6
513.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 447.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
161.3
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
25.4
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.1
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
10%
1.7
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
32.1
40%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 086.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Guangdong VTR Bio-Tech Co Ltd
SZSE:300381
Average EV/EBITDA: 3 647.5
32 527.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 262.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.7
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.3
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
55.1
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
146.4
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Guangdong VTR Bio-Tech Co Ltd
SZSE:300381
Average EV/EBIT: 3 652.5
32 527.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 011.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
30%
0.7
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.2
13%
1.4
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
56.7
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
177.6
N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 310,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.